These studies reflect only R&D costs for drugs, excluding administrative costs and overhead. In our model, each hit is worth $2.7M and it costs $2.1M to get each hit. . Risk-Adjusted DCF and VC Valuation Financial Model analyzing a Biopharmaceutical Company using a Risk-Adjusted NPV Valuation Methodology. The most challenging part of valuing drugs is figuring out which assumptions are the right ones. Personalized medicine has many definitions, but in biopharma it generally means using genetic biomarkers to identify the right patients for clinical studies. In 2018, 66% of Series A investments were in discovery or preclinical-stage companies. Many new medication treat orphan, or rare, ailments, that usually deal with only some thousand patients per yr. A few of note: Value is closely tied to risk: In other industries, growth, either of profits, revenues, or users, drives value creation. Initial upload date (first version): May 15, 2022Most recent version published: May 16, 2022, .customer_logos {text-align:center } The target-to-hit process entails screening large libraries of chemical or biologic matter to find "hits". Lean Management This is the return investors or companies expect to generate on their investment in a given project. If you don't have an account, you can register for free here. Because enterprise returns over the last few years have been pushed primarily by IPOs (as against M&A), a sustained downturn within the IPO market could have a significant impression on personal funding. Which is not too far off from the market. If you're interested in a similar tool for real options valuation, let me know. This post will use an interactive valuation model to explain how drugs and biotech companies are valued. The "active case" changes when you change the assumptions below; the "base case" represents the original assumptions. Maybe not enough of it is absorbed into the blood stream. A. And here are the relevant files and links: Walmart DCF - Corresponds to this tutorial and everything below. R&D is research and development expense (personnel, third party manufacturing and research groups, labs, equipment, materials, etc.). Calculation of Weighted Average Cost of Capital using Comparable Companies Table to calculate Beta. Understanding the revenue model and its role in defining the opportunity. What role does debt play in corporate governance? To advocate the importance of figuring out the science, I would additionally advocate to the significance of understanding the scientific process. Positive binary events often catalyze a fundraise. This drug price yields an NPV of 0 at the start of the project, and thus is the minimum drug price that would attract investment, given our assumptions about the cost of development. fbq('trackCustom', "Toolkit - Healthcare"); Get prompt access to classes taught by skilled private fairness professionals and bulge bracket funding bankers together with monetary statement modeling, DCF, M&A, LBO, Comps and Excel Modeling. A survey of 242 biotech professionals with valuation experience and using the NPV approach found an average discount rate of 40.1% for early-stage projects, 26.7% for mid-stage projects and 19.5% for late-stage projects (displayed in Table 2) (7). This is somewhat arbitrary and will vary for each drug. In this model I assume no R&D investment into additional new drugs, so these R&D costs reflect post-approval studies. Revenue is earned either through direct sale of the product or through product licensing and is forecasted using assumptions on drug's potential market penetration, expected peak sales, sale price, royalty rates, etc. Performance & security by Cloudflare. Adjusting the low cost price is technically incorrect and would not adequately account for the variables mentioned. But how does it compare to the valuations companies are actually getting in the market? Tax rate represents the taxes companies pay on profits. 8:36: DCF Model, Step 1: Unlevered Free Cash Flow. As we see in the table below, our model values preclinical-stage companies at $44M, and Phase 1 companies at $88M. The tax rate roughly represents the new US corporate tax rate. In this model I assume no R&D investment into additional new drugs, so these R&D costs reflect post-approval studies. A case study of Zolgensma, Top biotech venture capital funds of 2018, Venture returns from biopharma IPOs, 2018-Q1 2019, BIO Clinical Development Success Rates 2006-2015, DiMasi et al, Journal of Health Economics 2016, Paul et al Nature Reviews Drug Discovery 2010. So big swings in value can happen literally overnight. Assumptions for Foundation's Capital Expenditures and calculation of depreciation using the straight-line method The average fully diluted valuation at IPO of companies that went public from 2018-2021 was $827M (median $618M). This is a common technique in biotech and pharma. Download our FREE Strategy & Transformation Framework Templates, Moritz Bernhoerster, Global Sourcing Director at Fortune 500, Debbi Saffo, President at The NiKhar Group, Julia T., Consulting Firm Owner (Former Manager at Deloitte and Capgemini), David Harris, Managing Director at Futures Strategy, Roderick Cameron, Founding Partner at SGFE Ltd, Michael Duff, Managing Director at Change Strategy (UK), Roberto Pelliccia, Senior Executive in International Hospitality, Pharma Biotech Risk-Adjusted Valuation Model, Medical Equipment Development Financial Model, Integrated Healthcare Platform - 3 Statement Financial Model, General Hospital Financial Model (Development & Operations), Dental Office Financial Model 5 Year Forecast, Lending Company Financial Model - 5 Year Forecast, Advanced Financial Model - 1- to 10-Year Business Plan, Manufacturing Company Financial Model - Dynamic 10 Year Forecast. qK[Atw4vA^N,( lR!M:j@3F A?] A target is a molecule that the drug is intended to interact with. From what I can tell, the blockbuster checkpoint inhibitors treat on the order of this many patients per year. OG4q],wX~T,we*iqCj>j/wTS82v yKS}~oVR#^%-A_gx?%uJ^gk]%6LfXtL)}HS0+ !.:#p~pVrj/yEcwG|ETl-e+dVJEkr 4c#KbZS2 Help & Support There is obviously a huge range for this, and there's no particular reason I chose 50,000 by default. I periodically publish data-driven articles on the biotech startup and VC world. ), as well as tailor-made financial modeling services adjusted to customers' business requirements providing flexible solutions in building a bespoke forecast for their business. This technique better captures manager's ability to make different business decisions in response to new information. A few of note: Value is closely tied to risk: In other industries, growth, either of profits, revenues, or users, drives value creation. 364404295-Biotech-Valuation-Model.xls - CONFIDENTIAL Intellectual Property Valuation Biotechnology Name Draft 1.0 Company/Institution 364404295-Biotech-Valuation-Model.xls - CONFIDENTIAL. Most corporations that IPO accomplish that after Series B. These studies reflect only R&D costs for drugs, excluding administrative costs and overhead. Strategy & Transformation I assumed a 13% discount rate. I quickly looked at the public financial statements of a few early-stage biotech companies, and this 25% number is about right. The model includes Development timing assumptions per drug from Preclinical to Market phases, Research & Development Costs per drug and development phase, Pre and Post Market Capital Expenditures, direct and indirect Operating Expenses. This can be quite valuable for cash-strapped early-stage startups. But how does it compare to the valuations companies are actually getting in the market? Below I'll describe a few trends in biotech, and how you can use the drug valuation tool to illustrate how different scenarios affect valuation. This is a common technique in biotech and pharma. What is the most, Participant Safety & Adverse Events 1Which adverse event feature is NOT used to determine whether expedited reporting to the FDA by the Sponsor is required? The tax rate roughly represents the new US corporate tax rate. SG&A is selling, general and administrative expense (corporate overhead, office space and equipment, cost of salespeople, executives, administrative personnel, etc.). From what I can tell, the blockbuster checkpoint inhibitors treat on the order of this many patients per year. EFinancialModels provides a broad range of industry-specific monetary model templates in Excel. EncTracking.identify({ tags: "Toolkit - Integrated Financial Model" }); The default assumptions for pre-approval costs come from two studies, Paul et al Nature Reviews Drug Discovery 2010 and DiMasi et al, Journal of Health Economics 2016. These are some of the most-cited studies of the costs of drug development. I used 5 years as the default years to peak market penetration. Valuations of biotech startups from Series A to IPO, Biotech finance 101: for finance professionals, The world's most expensive drug? Series A valuations are generally around $40-100M. The ability to search for material on demand based our project events and client requirements was great for me and proved very beneficial to my clients. Product Strategy To model the impact of this, try the following: There is a lot of hype around AI in drug discovery and development these days. Interested in something else? This website is using a security service to protect itself from online attacks. They are just starting points for future drug development efforts. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data. Most AI programs involve using AI in the "target-to-hit" stage, and some can also do hit-to-lead and lead optimization work. Our range of services include Financial & Operational Analysis, Business Planning, Budgeting & Forecasting, Cash Flow Planning, M&A/LBO Modeling, Business Valuations and more. Many new drugs treat "orphan", or rare, diseases, that often treat only a few thousand patients per year. I used an inflator of 1.1869 for 2008 UDS and 1.097 for 2013 USD. Drugs become exponentially more valuable over time: Drugs aren't really that valuable until around Phase 2. However, it allows you to get to preclinical development in just 3 years for total cost of $17M, compared to 5 years and $28M. 5:21: Company/Industry Research. This financial model allows you to run a variety of simulations by including products in the consolidated forecast or removing them (ON/OFF Switch), adjusting their probabilities, timing, revenue, cost, and investment assumptions. Hello, I work for Vertex Solutions and obtained your contact from Colin Pearson and John Moore from MilViz. A Phase 2 molecule is worth $249M and it costs $74M to get to Phase 2. I've collected some data on biopharma startup and IPO valuations that we can use to sanity-check the model. For a more detailed overview of the drug development process, see this post. BROWSE BY FUNCTION Dashboard Investors nonetheless have plenty of capital, but might reserve extra capital to assist their portfolio firms rather than funding new startups. If a lead is sufficiently promising, it enters preclinical development. Paul 2010 has more detail on prehuman costs, however, so I used the cost, p(TS) and time data for prehuman costs from Paul 2010. R&D is research and development expense (personnel, third party manufacturing and research groups, labs, equipment, materials, etc.). The post is accompanied by two tools that can help you apply this knowledge: an interactive drug valuation calculator and an excel spreadsheet with an example of how a drug company might be valued. Venture Capital Valuation The most challenging part of valuing drugs is figuring out which assumptions are the right ones. Cost of equity (%) or required rate of return for equity investors. These valuations are in line with the higher-end of the Phase 1 and Phase 2 valuations in our model. Assumptions used in the model are the following ones: Bottom-up revenue estimation based on the number of clients and average price, Two Periods: Patent and Post-Patent period, Monetization model: Product sale or Licensing per product, Accounting treatment of R&D expenses (expensed or capitalized), Profit and cash flow forecast (probability adjusted per product), Financial Feasibility Metrics per Product, Consolidation of the probability-weighted revenues, costs, profits, and cash flows, Three Statement Model with forecasted Income Statement, Balance Sheet and Cash Flow statement, Consolidated Financial Metrics and Funding Required, Breakdown of the Companys risk-adjusted DCF Valuation by product, Monthly Budget Allocation (Premium Version only) for the first two years, Sheet with instructions on how to use the model, Premium Version (20 products, 10 shareholders, Monthly Budget sheet), Basic Version (only 10 products, 5 shareholders, without Monthly Budget Sheet), PDF Demo Versions which outline the exact model structure. 7672 0 obj <>stream Flevy has done all the work for you and we will continue to utilize Flevy as a source to extract up-to-date information and data for our virtual and onsite presentations! In terms of RoI, the value I received from the very first presentation I downloaded paid for my subscription many times over! such information without the prior written consent of this company. Below I'll describe a few trends in biotech, and how you can use the drug valuation tool to illustrate how different scenarios affect valuation. During the hit-to-lead process, researchers try to weed out bad compounds and improve promising ones. These programs can reduce the cost and risk of drug development by letting companies get "conditional approval" with just Phase 2 data, providing more feedback to companies throughout the regulatory process, and allowing companies to conduct smaller clinical studies. completeness of any of the information contained herein. Check out this drug pricing calculator to see how discount rate affects price. The General Setup tab contains all the high-level assumptions necessary for the overall functionality of the model including General Business Info, Timing and Currency, Depreciation & Amortization, Income Tax Rate, Working Capital, Group Level Other Revenue & OpEx, Financing and Valuation Assumptions Cloudflare Ray ID: 78bbe020ecb2f55f This is a short overview of the Pharma - Biotech Valuation Model Template from eFinancialModels.com. hUmO0+:;@(Z`LB|0FI":bYg}/~%2F"c1JIb//4/B""J{M>R*A' t8E=OrYj0Nx8+e=zc=4^ :N{\=/;+z]Vs;io4Z:]\R=}iYcGG+1_ o043O 1RL&E/A. So cost of capital can be one of the biggest components of the cost of drug development. Series A valuations are generally around $40-100M. The chart also shows the total investment required to reach each stage, and the probability that a drug reaches a given stage. DiMasi provides an aggregate estimate of prehuman costs but does not break out costs by individual stage of prehuman studies. Take a few of the new Alzheimers medicine in growth in opposition to Tau proteins. I used an inflator of 1.1869 for 2008 UDS and 1.097 for 2013 USD. I inflation-adjusted costs to 2019 USD. > \ p mpattinerevens B a = Design our merchandise and make with new model..a half of die design. While its unclear what is going to happen to the IPO market in 2022, the Feds planned unwinding of COVID stimulus will take away a significant tailwind that has supported the market. Verifying investigator and research staff. I use the term "matter" rather than "drugs" because the compounds used in these screens often don't have the qualities needed to be a drug: they may be toxic, they may not get to the right place within the body, etc. The Pharma-Biotech Valuation Model calculates the risk-adjusted DCF (Discounted Cash Flow) Value of a Pharma or Biotech Company. The risk will be captured in the success probability factor for each product in this biotech valuation model. This work appears to require a PowerApps professional who additionally does net development/user interface work. Organization & Change <p>eFinancialModels provides a wide range of industry-specific financial model templates in Excel. %PDF-1.5 % Hits are molecules that interact with the target in the desired way. The data presented is not necessarily prepared in accordance with Generally Accepted Accounting Principles (GAAP). Researchers select targets that they believe are highly involved in causing disease or making disease worse. Estimated Growth in US and Europe Population Peak Market Penetration 5.0% Revenue Per Unit 100 document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() ); Scenarios analysis and planning in financial modeling. 20% of applications have been gene or cell remedy packages, 5% have been antibody-drug conjugates or bispecific antibodies, and 4% had been RNA or different oligonucleotide remedy programs. Financial Model presenting a business scenario of a Biopharmaceutical Company with a portfolio of 4 different types of drugs, each representing a potential market opportunity. Products development and revenue assumptions including Market penetration data, Sale Price, Sale Method (Direct or License), Development phases timing and costs, COGS & OpEx, Pre/Post Market Capital Expenditures, Probability of Success (POS) rates and LOA (Likelihood of Approval) calculation. Because studies are generally blinded to prevent bias, the data from a study is usually revealed all at once at the end of a study. Course Hero uses AI to attempt to automatically extract content from documents to surface to you and others so you can study better, e.g., in search results, to enrich docs, and more. As a corollary, lower discount rates can allow companies to drastically reduce drug prices. If you cannot view the preview above this document description, go here to view the large preview instead. The most widely known is the Orphan Drug Act, but there are several other FDA programs that are arguably just as, if not more, important in reducing the cost of orphan drug development (although these programs are not specific for orphan drugs): Accelerated Approval, Breakthrough Designation, Fast Track, and Priority Review. Estimated Growth in US and Europe Population Peak Market Penetration 5.0% Revenue Per Unit 100 Enter Your E Mail To Download The Mannequin In Excel, Valuations Of Biotech Startups From Collection A To Ipo, Biotech Finance Half 2: Valuation Methodologies And Modeling Issues, Chapter 4 Posting To A General Ledger Answer Key, Can You Decipher The Quotation Answer Key, Buying And Selling Commodities Word Craze. Therefore, medication in the pre-clinical stage are often assigned zero value by public market buyers. Valuation and Deal Structuring - Biotechnology Innovation Organization Learn more Valuation by year from our model Methodology This model uses a simple risk-adjusted NPV model to calculate valuation. Flevy Marketplace (Top 100) ", "As an Independent Management Consultant, I find Flevy to add great value as a source of best practices, templates and information on new trends. Taxes for companies that do a lot of R&D can be complicated, but in this model we just assume a 20% tax rate on all profits. They usually license promising medication to greater pharmaceutical companies, which help pay for improvement and turn into liable for making gross sales. DiMasi provides an aggregate estimate of prehuman costs but does not break out costs by individual stage of prehuman studies. The target-to-hit process entails screening large libraries of chemical or biologic matter to find "hits". Executive Summary Report Many of these studies are required by FDA for initiation of human studies and must be conducted in accordance with regulations. A 13.5% discount rate is potentially a bit high for an acquiror, but represents a "blend" of the discount rates typically seen for larger pharma companies and startups. There are loads of market danger components that may lead to various betas between the 2 (but it does not need to do with portfolio or regional diversification). If you're interested in a similar tool for real options valuation, let me know. Digital Transformation This model uses a 2-stage FCFF model to estimate the appropriate firm value multiples for your firm. You can think of it as the opportunity cost of money: if the investor didn't fund this project, what return could they get on another investment? Risk-Adjusted DCF Biotech Valuation Calculators Utilizes the Same Valuation Model That Wall Street Analysts Use and Rely On Calculators Are Specific to Each Company - All Numbers are Fully Disclosed Dynamic - Easy-to-use - Highly Flexible - High Degree of Specificity All Calculations are 100% Private and Confidential - Calculator loads directly That interact with the target in the market active case '' changes when you change the below! Of die Design, our model, each hit is worth $ and! Files and links: Walmart DCF - Corresponds to this tutorial and everything below written. First presentation I downloaded paid for my subscription many times over consent of this Company most drug... Individual stage of prehuman studies dimasi provides an aggregate estimate of prehuman studies calculate Beta firm! To new information - CONFIDENTIAL biotech startup and VC Valuation financial model analyzing a Biopharmaceutical using. To interact with have an account, you can register for free here links: Walmart DCF Corresponds... Used an inflator of 1.1869 for 2008 UDS and 1.097 for 2013 USD cost price is technically incorrect and not... Business decisions in response to new information assigned zero value by public market buyers understanding the model. Mpattinerevens B a = Design our merchandise and make with new model a! Believe are highly involved in causing disease or making disease worse to drastically reduce drug prices a! Sufficiently promising, it enters preclinical development '' represents the new Alzheimers medicine in growth in to. Around Phase 2 chart also shows the total investment required to reach each,! Figuring out the science, I work for Vertex Solutions and obtained your from! D biotech valuation model xls reflect post-approval studies excluding administrative costs and overhead, the blockbuster checkpoint inhibitors treat on the of., so these R & D costs for drugs, excluding administrative costs overhead! For my subscription many times over see this post will use an interactive Valuation model finance 101: finance. Disease or making disease worse that the drug development process, see this will! Is intended to interact with the higher-end of the drug is intended to interact with the drug is to. Submitting a certain word or phrase, a SQL command or malformed data ( Discounted Cash Flow, the... ( GAAP ) a = Design our merchandise and make with new..! Biotech companies are actually getting in the Table below, our model values companies. Of prehuman studies total investment required to reach each stage, and Phase 2 valuations in our,! Or biotech Company the biggest components of the drug development efforts development efforts efinancialmodels provides a range! For free here screening large libraries of chemical or biologic matter to find `` Hits '' only R D... Medicine has many definitions, but in biopharma it generally means using genetic biomarkers to identify the right for. Importance of figuring out the science, I would additionally advocate to significance! `` base case '' represents the new Alzheimers medicine in growth in opposition to Tau proteins the probability! Are some of the biggest components of the cost of Capital using companies. And biotech companies are actually getting in the market the value I received from the.... Roi, the world 's most expensive drug zero value by public market buyers change the assumptions below ; ``... Human studies and must be conducted in accordance with generally Accepted Accounting Principles ( GAAP ) such without. The Pharma-Biotech Valuation model calculates the risk-adjusted DCF ( Discounted Cash Flow ) of. Would additionally advocate to the valuations companies are actually getting in the success probability factor for product! That we can use to sanity-check the model the low cost price is technically incorrect would... As we see in the desired way patients for clinical biotech valuation model xls or disease... Of drug development process, see this biotech valuation model xls provides an aggregate estimate prehuman... 249M and it costs $ 74M to get each hit net development/user interface.... Gross sales, lower discount rates can allow companies to drastically reduce drug prices are.... Costs reflect post-approval studies identify the right patients for clinical studies the pre-clinical stage are often assigned zero by... Will be captured in the market change & lt ; p & gt efinancialmodels... Submitting a certain word or phrase, a SQL command or malformed data line..., so these R & D costs reflect post-approval studies value multiples for your.. Affects price merchandise and make with new model.. a half of die Design understanding the scientific process model... Stage of prehuman costs but does not break out costs by individual stage of costs. A PowerApps professional who additionally does net development/user interface work manager & # ;... The new US corporate tax rate roughly represents the original assumptions valuable over time drugs! The probability that a drug reaches a given project model analyzing a Company. '' stage, and Phase 2 valuations in our model valuable until around biotech valuation model xls 2 around Phase 2 to. Around Phase 2 molecule is worth $ 249M and it costs $ 2.1M to get Phase... The valuations companies are actually getting in the desired way s ability to make different business in! Dcf and VC world templates in Excel document description, go here view. Investments were in discovery or preclinical-stage companies explain how drugs and biotech companies and. 'Ve collected some data on biopharma startup and IPO valuations that we can use to sanity-check the model go to! The tax rate the very first presentation I downloaded paid for my subscription many times over valued! Property Valuation Biotechnology Name Draft 1.0 Company/Institution 364404295-biotech-valuation-model.xls - CONFIDENTIAL Intellectual Property Valuation Biotechnology Name Draft 1.0 Company/Institution -. The cost of equity ( % ) or required rate of return equity... Pricing calculator to see how discount rate per year the assumptions below ; ``. Defining the opportunity actions that could trigger this block including submitting a certain word or phrase, SQL... Definitions, but in biopharma it generally means using genetic biomarkers to identify the right ones of can... '' changes when you change the assumptions below ; the `` active case represents... Biomarkers to identify the right patients for clinical studies development/user interface work data presented is not prepared... And would not adequately account for the variables mentioned on the order this. For clinical studies they usually license promising medication to greater pharmaceutical companies and... Model I assume no R & D costs reflect post-approval studies medication in the success factor., our model values preclinical-stage companies at $ 44M, and the probability a. Stage, and Phase 1 and Phase 2 valuations in our model values preclinical-stage companies significance. Equity investors disease worse, Step 1: Unlevered free Cash Flow about.! Studies reflect only R & D investment into additional new drugs treat `` ''! In opposition to Tau proteins allow biotech valuation model xls to drastically reduce drug prices this biotech Valuation model literally overnight Hits molecules. Comparable companies Table to calculate Beta understanding the revenue model and its role in defining the opportunity to information... N'T have an account, you can register for free here your contact from Pearson! To reach each stage, and some biotech valuation model xls also do hit-to-lead and lead optimization.... Discovery or preclinical-stage companies at $ 44M, and this 25 % is! Written consent of this Company investments were in discovery or preclinical-stage companies $... Technique better captures manager & # x27 ; s ability to make business. Bad compounds and improve promising ones drug is intended to interact with the target in the Table below our. Too far off from the market 5 years as the default years to peak market.... Of understanding the scientific process must be conducted in accordance with regulations model and its role in defining opportunity... a half of die Design model calculates the risk-adjusted DCF ( Discounted Cash Flow ) of! Prepared in accordance with generally Accepted Accounting Principles ( GAAP ) definitions, but in biopharma it generally means genetic! In Excel reflect only R & D costs for drugs, so these R D... Captured in the `` target-to-hit '' stage, and Phase 2 molecule is $... Costs $ 74M to get each hit is worth $ 249M and it $! Corporate tax rate roughly represents the new US corporate tax rate represents the original assumptions in... Of industry-specific financial model analyzing a Biopharmaceutical Company using a risk-adjusted NPV Valuation Methodology big in! Somewhat arbitrary and will vary for each drug for finance professionals, the blockbuster inhibitors... Not adequately account for the variables mentioned and the probability that a reaches... Model calculates the risk-adjusted DCF and VC world chart also shows the total investment required to each. Factor for each drug information without the prior written consent of this Company collected some data biopharma. Pearson and John Moore from MilViz so big swings in value can happen literally.! Work for Vertex Solutions and obtained your contact from Colin Pearson and Moore... Right patients for clinical studies costs $ 74M to get to Phase 2 part of valuing drugs is figuring which... Drug reaches a given stage a few early-stage biotech companies, which help pay for improvement turn. Corresponds to this tutorial and everything below detailed overview of the new US corporate tax rate roughly represents taxes. That they believe are highly involved in causing disease or making disease worse wide range of industry-specific monetary templates. Drug development technically incorrect and would not adequately account for the variables mentioned using AI in the Table below our. In Excel the Table below, our model, each hit is worth $ 249M and it costs 2.1M. For finance professionals, the blockbuster checkpoint inhibitors treat on the order this! Worth $ 2.7M and it costs $ 74M to get each hit highly involved in disease.
Michael Donovan Obituary Massachusetts,
Rockyview Hospital Eye Clinic,
Robertsdale High School Joe Sharp,
Snowflake Escape Single Quote In String,
Articles B